Pfizer Inc. (NYSE:PFE) Shares Acquired by Generali Investments Towarzystwo Funduszy Inwestycyjnych

Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position in shares of Pfizer Inc. (NYSE:PFE) by 3.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 46,500 shares of the biopharmaceutical company’s stock after purchasing an additional 1,600 shares during the quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Pfizer were worth $1,178,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Clarity Asset Management Inc. bought a new position in Pfizer during the fourth quarter worth $27,000. Gould Capital LLC lifted its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Bayforest Capital Ltd bought a new position in Pfizer during the first quarter worth $28,000. North Capital Inc. bought a new position in Pfizer during the first quarter worth $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer in the fourth quarter worth $30,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price on the stock. Bank of America increased their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Wolfe Research increased their target price on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research report on Wednesday, April 30th. Morgan Stanley increased their target price on Pfizer from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 30th. Finally, Redburn Atlantic dropped their target price on Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $28.28.

Pfizer Trading Up 0.9%

NYSE:PFE opened at $23.49 on Friday. The stock has a fifty day simple moving average of $24.36 and a 200 day simple moving average of $24.57. The firm has a market capitalization of $133.55 billion, a price-to-earnings ratio of 17.02, a price-to-earnings-growth ratio of 0.85 and a beta of 0.52. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.32. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.3%. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.